- Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158Wu, X.; Mao, Y.; Xu, N.; Bai, Y.; Wang, D.; Chen, X.; Yin, X.; Deng, Y.; Yang, J.; Zhang, J.; Tang, J.; Huang, Y.; Li, J.; Xu, M.; Li, N.; Mao, Y.; Gozman, A.; Xu, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158Mao, Y.; Wu, X.; Xu, N.; Bai, Y.; Wang, D.; Chen, X.; Yin, X.; Deng, Y.; Yang, J.; Zhang, J.; Tang, J.; Huang, Y.; Li, J.; Xu, M.; Li, N.; Mao, Y.; Gozman, A.; Xu, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Sitravatinib plus tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer (NSCLC)Gao, B.; Ma, Z.; Yu, X.; Huang, D.; Zhao, J.; Day, D.; Body, A. L.; Zhou, Q.; Chu, Q.; Pan, H.; Cui, J.; Li, H.; Sun, J.; Zhang, J.; Fei, C.; Wu, Y-L.ESMO Targeted Anticancer Therapies Congress (TAT), ELECTR NETWORK, 2022-03-07 To 2022-03-08.被引 2
会议论文
Phase 2 study of tislelizumab monotherapy in previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: Gynecological cancer subgroup
15阅读
